title: [Current status in molecular-targeted therapy and IFNα for renal cell carcinoma in Japan].
abstract: It has been two years since molecular-targeted therapy became available for advanced renal cell carcinoma (RCC) in Japan. It shall be validated whether molecular-targeted therapy really improved the prognosis of patients with advanced RCC in the near future. Here we review the two phase III clinical studies that demonstrated the superiority of sunitinib and temsirolimus over IFNα and discuss optimal therapy including IFNα for advanced RCC in the future biomarker era.
authors.affiliation: The Department of Urology, Kinki University School of Medicine
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nozawa
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D016898:Interferon-alpha / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy / Q000379:methods*; D011758:Pyrroles / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D016898:Interferon-alpha; D011758:Pyrroles; C401859:temsirolimus; D000077210:Sunitinib; D020123:Sirolimus